

Table EU Approved / positive opinion biosimilars by molecule January 2023

(not available in all EU-countries) (status CHMP-meeting January 21, 2023, 79 products, from which 1 pending EC approval)

Molecule	Reference	Biosimilar(s)
Adalimumab	Humira	Amgevita, Amsparity, Halimatoz, Hefiya, Hukyndra, Hulio, Hyrimoz, Idacio, Libmyris, Imraldi; Yuflyma (new formulation)
Bevacizumab	Avastin	Abevmy, Alymsys, Aybinto, Equidacent; MVasi, Onbevzi, Oyavas, Zirabev, Vegzelma
Enoxaparine	Clexane	Inhixa
Epoetine alfa	Eprex	Absaemed, Binocrit, Epoetin alfa Hexal, Retacrit, Silapo
Etanercept	Enbrel	Benepali, Erelzi, Nepexto
Filgrastim	Neupogen	Accofil, Filgrastim Hexal, Grastofil, Nivestim, Ratiograstim, Tevagrastim, Zarzio
Follitropin alfa	Gonal-f	Bemfola, Ovaleap
Infliximab	Remicade	Flixabi, Inflectra, Remsima, Zessly
Insulin Aspart	Novo Rapid	Insulin Aspart Sanofi; Kixelle, Truvelog Mix30
Insulin glargine	Lantus	Abasaglar, Semglee
Insulin Human	Actrapid	Inpremia
Insulin Lispro	Humalog	Insulin Lispro Sanofi
Pegfilgrastim	Neulasta	Cegfila, Fulphila, Grasustek, Nyvepria, Pelgraz, Pelmeg, Stimufend, Udenyca, Ziextenzo
Ranibizumab	Lucentis	Byooviz, Ranivisio, Ximluci
Rituximab	Mabthera IV	Blitzima, Ritemvia, Rixathon, Riximyo, Ruxience, Truxima
Somatropine	Genotropin	Omnitrope
Teriparatide	Forsteo	Movymia, Terrosa, Livogiga, Sondelbay, positive opinion: Kauliv
Trastuzumab	Herceptin IV	Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera, Zercepac

Source: EMA website

https://www.ema.europa.eu/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar

Accessed: January 21. 2023_LB

15 Biosimilar-products in the licensing pipeline at EMA (Status: 3 February 2023).

Aflibercept (1x); Bevacizumab (1x), Eculizumab (2x), Filgrastim (1x), Insulin human (1x), Natalizumab (1x); Pegfilgrastim (2x), Ranibizumab (1x), Teriparatide (1x), Tocilizumab (3x); Trastuzumab (x), Ustekinumab (1x)

For a comparison with US/FDA (March 2022; no update available at this time) see:

<https://www.biosimilarsip.com/2022/03/14/how-the-u-s-compares-to-europe-on-biosimilar-approvals-and-products-in-the-pipeline-updated-march-14-2022/>

FDA approved biosimilars (updates weekly by Stanton Mehr)

<https://biosimilarsrr.com/us-biosimilar-filings/>

2023_01_21Table EU licensed biosimilars by molecule_January 2023